必威体育精装版成人急性淋巴细胞白血病诊治进展.ppt

* Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALLXII/ECOG E2993. Blood, 2005 106: 3760-3767. * Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia .Blood，2006，107:1116-1123. * Treatment of Adult Acute Lymphoblastic Leukemia. American Society of Hematology, 2006. * Treatment of Adult Acute Lymphoblastic Leukemia. American Society of Hematology, 2006. * * 参见Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ，2008，41：439–446. * 参见Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ，2008，41：439–446. * Aversal, et al. Journal of Clinical Oncology, 2005, 23: 3447-3454. * Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion. American Society of Hematology, 2007. * Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ，2008，41：439–446. * The 5-year DFS after allogeneic SCT according to degree of chronic GVHD. No chronic GVHD 22 (10-36) %, limited chronic GVHD 53 (38-69) %, and extensive chronic GVHD 27(1-54) %. * Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion. American Society of Hematology, 2007. * Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study。 Blood，2007，109：944-950. * * Ph+ALL单用化疗5年OS﹤10％。 在格列卫应用之前，MRC UKALLXII/ECOG E2993 结果显示， Ph+ALL 患者CR1期，有HLA相合供者进行Allo-HSCT，无HLA相合供者进行化疗，5年OS总体上在25％左右。多家文献报道异基因移植治疗CR1期Ph+ALL 患者，DFS可达30%-65%。 * The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457. 29例Ph+ALL 患者诱导治疗CR者给予格列卫400-600mg/d，与巩固化疗同时率为79